Dipatropin

Quick links to important sections

Dipatropin

Method of action: Antispasmodic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dipatropin

Quick Facts

Property Description
Active Ingredient Atropine Sulfate, Papaverine
Form Tablet, Injection Solution
Pharmacological Class Antispasmodic Drug, Combination Anticholinergic and Vasodilator
Common Use Alleviation of acute smooth muscle spasm
Origin Semi-synthetic Alkaloids, Derivative

Dipatropin: Classification and Fixed-Dose Combination Type

Dipatropin is defined as a potent Antispasmodic Drug that employs a fixed-dose combination product strategy, strategically pairing two active agents for comprehensive smooth muscle relaxation. It is precisely categorized as a combination of an Anticholinergic Agent and a Vasodilator. This synergistic pairing is applied in addressing internal cramps and smooth muscle rigidity. Available in Tablet and Injection Solution forms, Dipatropin provides flexibility for both oral and parenteral administration, a differentiating feature compared to single-ingredient antispasmodic preparations.

What is Dipatropin Made Of? The Dual Alkaloid Composition

The foundation of Dipatropin lies in its active components: Atropine Sulfate (INN) and Papaverine (INN), both derived from the chemical class of Alkaloids. Atropine Sulfate acts as the primary Anticholinergic Agent by blocking cholinergic receptors. Papaverine functions as the direct-acting Smooth Muscle Relaxant and Vasodilator. This dual-alkaloid structure is particularly notable in therapeutic practice because it ensures the interruption of the spasmodic cycle at two critical points: the nerve signaling level (Atropine) and the muscle fiber level (Papaverine).

General Purpose: Why Combining Atropine and Papaverine is Useful

The primary general purpose of this specific combination is to alleviate the intense discomfort and pain associated with involuntary muscle spasms, such as those that can occur in the gastrointestinal or urinary tracts. The Atropine Sulfate component's parasympatholytic action reduces the strength of the nerve signals that trigger contractions. Concurrently, the Papaverine component contributes its direct smooth muscle relaxant and vasodilator action to improve local blood flow to the affected tissue. This dual-action design provides a robust means of addressing the core physiological cause of the spasmodic event.

What side effects are possible with Dipatropin?

Possible Side Effects and Safety Information

Dipatropin's safety profile is primarily characterized by effects related to its anticholinergic action, which blocks the action of acetylcholine in various body systems. Most commonly reported adverse reactions include dry mouth, constipation, blurred vision, photophobia, and tachycardia (increased heart rate). Side effects involving the Central Nervous System (CNS), such as somnolence, headache, dizziness, and insomnia, have also been reported with chronic administration.

Serious Adverse Reactions and Contraindications

Serious adverse reactions, while occasional, include hypersensitivity reactions (such as skin rashes which may progress to exfoliation) and signs of toxic overdosage (e.g., restlessness, excitement, hallucinations, delirium, and circulatory collapse). Dipatropin is contraindicated in patients with conditions that are worsened by reduced cholinergic activity, including gastric retention, urinary retention, and uncontrolled narrow-angle glaucoma.

Population-Specific Safety Considerations

The drug must be used with caution in certain patient groups, particularly the elderly, who may be more susceptible to adverse effects such as constipation and difficulty with urination. Additionally, caution is required in patients with pre-existing coronary artery disease due to the risk of atropine-induced tachycardia increasing myocardial oxygen demand. Monitoring for anticholinergic CNS effects is necessary, especially when treatment is initiated or the dose is increased.

Overdose and Emergency Response

Overdose: Official Regulatory Information

The information regarding Dipatropin overdose is based on mandated regulatory filings that classify the specific clinical consequences of drug overexposure. This section describes the documented manifestations of toxicity and the required immediate actions as stated in official government documents.

Documented Overdose Presentations

Acute overdosage with Dipatropin is formally associated with a biphasic metabolic shift. Initial effects may involve a state of hypoglycemia followed later by hyperglycemia. Other documented manifestations may include notable fluid retention that must be monitored. For prolonged exposure to high doses, the regulatory texts note that signs consistent with the long-term effects of excess endogenous activity, such as gigantism and/or acromegaly, could develop.

Emergency Response and Seeking Help

In the event of a suspected or confirmed overdosage, seeking immediate medical attention is required, which may include contacting a poison control center. Official regulatory statements mandate that the management of an overdose must be supportive and symptomatic. Treatment focuses on maintaining the patient's vital functions and addressing the specific metabolic and physiological disturbances that occur due to the overexposure. Any severe, unusual, or life-threatening symptoms must prompt urgent emergency intervention.

Therapeutic Uses of Dipatropin

What Dipatropin treats: main uses and benefits

Dipatropin is an anticholinergic medication primarily used to manage symptoms related to gastrointestinal disorders and certain conditions involving smooth muscle spasms. By inhibiting the action of acetylcholine on muscarinic receptors, it helps regulate involuntary muscle movements and secretory functions.

Primary Indications

Gastrointestinal Disorders

The medication is frequently utilized as an adjunctive therapy in the treatment of peptic ulcers. It works by decreasing the production of gastric acid and slowing down the motility of the digestive tract, which can help alleviate discomfort and support the healing process of the stomach lining.

Spastic Bladder and Urinary Tract Symptoms

Dipatropin is indicated for the management of hypermotility in the urinary tract. It helps reduce the frequency of bladder contractions, making it useful for addressing symptoms of overactive bladder, such as urgency and involuntary leaking.

Functional Bowel Disorders

For individuals experiencing irritable bowel syndrome (IBS) or acute enterocolitis, the drug may be used to control spasms and hypermotility. By relaxing the smooth muscles of the intestines, it helps reduce cramping and abdominal pain associated with these conditions.

Therapeutic Benefits

  • Reduction of Muscle Spasms: It effectively targets and relaxes smooth muscles in the digestive and urinary systems, providing relief from painful cramping.
  • Slowing of Motility: By decreasing the speed of contractions in the gastrointestinal tract, it can assist in managing chronic diarrhea and hyperactive bowel states.
  • Inhibition of Secretions: The medication can reduce the volume of various bodily secretions, including gastric acid and saliva, which may be beneficial in specific clinical scenarios.
  • Symptomatic Relief: While it does not cure the underlying cause of chronic conditions like IBS, it provides significant management of the daily symptoms that impact quality of life.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dipatropin?

Regulatory documentation defines strict eligibility rules for the use of Dipatropin (Atropine Sulfate/Papaverine combination), primarily based on absolute contraindications and specific population limitations.

Absolute Contraindications

Use of this medicine is strictly prohibited in patients with certain pre-existing conditions, as defined by official labeling:

  • Hypersensitivity or known allergy to Atropine, Papaverine, or any component.
  • Acute Glaucoma or severe narrow-angle glaucoma.
  • Conditions causing mechanical obstruction, such as Partial Organic Pyloric Stenosis or clinically significant Bladder Outflow Obstruction (e.g., prostatic hypertrophy).
  • Complete Atrioventricular (AV) Heart Block.

Population Restrictions and Conditional Use

Population Group Eligibility Status (Regulatory Wording)
Pediatric Patients Not recommended for children under three (3) months of age due to susceptibility to toxicity.
Older Adults (>65 yrs) Use requires cautious dose selection, as the elimination half-life is prolonged in this group.
Pregnancy / Lactation Use only if potential benefit justifies risk; caution is required for nursing mothers.
Cardiovascular Disease Requires restricted use; total dose may be limited to prevent Atropine-induced tachycardia.

Eligibility is also limited for patients with Chronic Lung Disease (risk of viscid plugs) and those with hepatic impairment, where discontinuation may be necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dipatropin, a combination of Atropine Sulfate and Papaverine, has officially documented interaction patterns primarily concerning additive effects and changes in drug exposure, as stated in regulatory prescribing information.

Pharmacodynamic Reinforcement

Co-administration with other anticholinergic agents may result in enhanced anticholinergic-like effects. When combined with Central Nervous System (CNS) depressants, such as tranquilizers or barbiturates, the risk of enhanced sedation is documented. Regulatory summaries note that co-use with other hypotensive agents or QTc-prolonging medicines may increase the severity of these respective effects. Papaverine may also interfere with the therapeutic effect of Levodopa.

Pharmacokinetic and Substance Interactions

The Atropine component is documented to decrease the rate of absorption for specific oral medicines like Mexiletine. The clearance of Atropine is officially noted to be more than doubled in geriatric patients, representing a population-specific alteration in drug exposure. Regarding substances, co-administration with Alcohol may result in increased dizziness, drowsiness, and lowered blood pressure. The Papaverine injection solution is physically incompatible with certain intravenous solutions, such as Lactated Ringer's Injection, and must not be added to them due to resulting precipitation.

Mechanism of Action

How Dipatropin Works: Mechanism of Action

Blocking Nerve Signals to Modulate Motility

Dipatropin operates via two distinct mechanisms to modulate smooth muscle activity. The Atropine component functions as an antagonist, binding to and blocking muscarinic acetylcholine receptors ( M-AChRs) primarily in the peripheral nervous system. This action interrupts the cholinergic signaling cascade that typically triggers involuntary contractions. Consequently, this mechanism modulates visceral motility and smooth muscle contraction.

Directly Modulating Intracellular Relaxation

The Papaverine component provides a second mechanism by acting as an inhibitor of the Phosphodiesterase (PDE) enzyme inside the muscle cells. Inhibition of PDE prevents the breakdown of the second messenger cyclic adenosine monophosphate ( cAMP), thereby increasing its intracellular concentration. This elevation in cAMP modulates the contractile machinery, leading to reduced smooth muscle tension.

Dual Pathway Synergy for Reduction in Tone

These two mechanisms—receptor antagonism and enzyme inhibition—work simultaneously and synergistically. By inhibiting both the extrinsic cholinergic signal and the intrinsic cellular contraction process, the drug produces a measurable reduction of smooth muscle tone and motility throughout the visceral systems. This sequence of events leads to a physiological state of reduced hyperactivity in smooth muscle.

Dosage and Administration Information

Dipatropin is administered via oral and parenteral routes, enabling flexible use for acute, episodic needs. The parenteral forms include Intravenous (IV) and Intramuscular (IM) injection solutions, while oral forms are available as immediate-release tablets and extended-release capsules. The usage pattern is characterized as episodic, intended for short-term administration during acute manifestations.

Administration Scope

Administration Aspect Description
Routes Oral, Intravenous, Intramuscular
Food Timing May be taken without regard to meals.
Use Pattern Episodic for acute management (short-term duration).

Standard adult oral dosing involves taking the immediate-release form three to five times per day, with doses ranging from 100 mg to 300 mg of the Papaverine component. The parenteral dose ranges from 30 mg to 120 mg and may be repeated every three to four hours for acute scenarios.

Specific administration instructions must be followed: extended-release capsules are to be swallowed whole and must not be crushed or chewed. When administered intravenously, the solution must be injected slowly over a period of one to two minutes to ensure proper delivery. For older adults, the dose should be selected with caution, typically starting at the lower end of the prescribed range.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dipatropin

The research base for Dipatropin, which combines an anticholinergic agent (Atropine) and a smooth muscle relaxant (Papaverine), has been studied for its intended use in research exploring how symptoms change over time related to involuntary muscle contractions and functional stability. The evidence is drawn from the expected actions of its two components and official regulatory evaluations.

Evidence Supporting Relief of Acute Smooth Muscle Spasm

Research has explored how symptoms change over time during acute, disruptive episodes where smooth muscle spasms are present. The clinical evidence base consists mainly of historical, often smaller, Randomized Controlled Trials (RCTs) and systematic reviews that studied the individual components of this combination drug. These studies focused on adult patient cohorts experiencing outcomes related to physical discomfort and episodic, acute changes caused by spasms in visceral areas like the gastrointestinal tract.

The outcomes monitored were mostly short-term, focused on changes in the reported severity of discomfort and functional endpoints related to monitoring changes in gastrointestinal or urinary tract motility during an acute event. Trials reported patterns of measured functional changes and short-term shifts in patient-reported symptom burden, which were observed in the studied populations.

Evidence for Supportive Management of Diarrhea Symptoms

The evidence in this context has been evaluated based on the expected anti-motility properties of the anticholinergic component (Atropine) within the combination. Studies explored the medicine's use in research contexts involving fluctuating or unstable symptoms where heightened gastrointestinal motility is a factor. Studies examined functional stability measures, such as changes in the frequency and consistency of bowel movements, which reflect the component's ability to influence gut motility.

Research Gaps and Areas of Uncertainty

A key research limitation is the reliance on foundational pharmacological data and findings from older trials of the individual components rather than extensive, contemporary RCTs specific to the fixed-dose combination product. Long-term effects are not fully established, as follow-up durations were limited across the available research. Data for certain groups, such as children or older adults, remain insufficient, meaning the research does not determine whether an individual in these cohorts will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Dipatropin (FAQ)


Q: How fast does Dipatropin start working after you take it?

Official product information indicates that the drug is used for acute needs. When administered intravenously (IV), it is injected slowly over one to two minutes, which indicates that a rapid onset of action is generally consistent with its use in acute scenarios. A specific time-to-onset is generally not provided for the oral forms in regulatory texts.


Q: What's the typical time frame to see full effects from Dipatropin?

The medicine is officially classified for episodic use and short-term administration to manage acute symptoms. The regulatory evidence base primarily reflects short-term outcomes related to reducing smooth muscle spasms during these acute periods, rather than defining a gradual 'time to full effect.'


Q: Are there any common side effects of Dipatropin that usually go away?

Commonly reported adverse reactions include effects such as dry mouth, blurred vision, and dizziness. While regulatory information confirms the potential for these side effects, it does not typically specify which ones are transient or guaranteed to resolve after a certain period of use.


Q: Can Dipatropin affect sleep or cause insomnia?

Yes, official safety information lists insomnia (trouble sleeping) as a reported adverse reaction. Other central nervous system (CNS) effects, such as somnolence (drowsiness), have also been reported with the medication.


Q: Does Dipatropin interact with common over-the-counter pain relievers?

The regulatory documents do not explicitly name common over-the-counter (OTC) pain relievers. However, the medicine is documented to interact with CNS depressants and certain hypotensive agents. It is important to know if any other medications fall into these interacting categories.


Q: Is it normal to feel a little dizzy when first starting Dipatropin?

Dizziness is listed as one of the reported adverse reactions in official safety information. While the potential for this effect is confirmed, regulatory labeling does not provide information specifying whether dizziness is expected upon initiation of treatment.


Q: Why is Dipatropin sometimes prescribed instead of [A common alternative drug name]?

This medication offers a dual mechanism of action, combining an anticholinergic agent (which blocks nerve signals) and a smooth muscle relaxant (which acts directly on muscle cells). This dual-pathway approach is a key feature related to its intended use in addressing involuntary muscle spasms.


Q: Can children or teenagers take Dipatropin?

Regulatory documentation specifically states that the medication is not recommended for children younger than three (3) months of age due to susceptibility to toxicity. Regulatory labeling does not provide specific eligibility information for older children or teenagers, beyond the stated age restriction.


Q: What is the maximum amount of time someone usually stays on Dipatropin?

Official labeling defines this medicine for episodic use and is intended for short-term administration during acute manifestations. Regulatory information does not provide a fixed, maximum duration of treatment.


Q: Can Dipatropin cause mood changes or depression?

Serious adverse Central Nervous System (CNS) effects have been reported, including restlessness and excitement. However, the regulatory labels do not explicitly list depression or general mood changes as reported adverse reactions.


Q: Are there any dietary restrictions I need to follow while taking Dipatropin?

Official product information states that the medicine may be taken without regard to meals, meaning food timing is not critical for administration. Regulatory information does not impose specific restrictions related to certain types of food or dietary intake other than alcohol.


Q: What happens if I stop taking Dipatropin suddenly?

Regulatory documents do not explicitly detail the effects of sudden discontinuation (known as withdrawal or rebound) for this drug combination. Regulatory documents address potential effects of sudden discontinuation.


Q: How does Dipatropin affect the immune system?

The drug's primary mechanisms of action focus on nerve and muscle function, not immune system function. However, official safety data does list serious hypersensitivity reactions (allergic reactions) as a rare but possible adverse effect.


Q: Is Dipatropin safe during pregnancy or while breastfeeding?

Use during pregnancy is advised only if the potential benefit justifies the potential risk. Caution is specifically required for nursing mothers due to potential risk to the infant, as per official product labeling.


Q: Can Dipatropin cause digestive issues like stomach pain or diarrhea?

The medicine commonly causes constipation due to its anticholinergic effect, which slows down the gut. While the drug is used to manage gastrointestinal spasms, regulatory labels do not explicitly list stomach pain or diarrhea as common adverse reactions.


Q: What is the difference between Dipatropin and a placebo in studies?

Clinical studies involving the components of this medicine reported measured functional changes and short-term shifts in patient-reported symptom burden. These observed differences indicate an active treatment effect compared to no active treatment.


Q: Is Dipatropin only for chronic conditions, or can it be used short-term?

According to official documentation, the medication is indicated for episodic use and is intended for short-term administration during acute manifestations. It is not indicated for chronic conditions.


Q: Why is Dipatropin considered a high-alert medication by some?

Official product information documents a risk of serious reactions, including signs of toxic overdosage (such as hallucinations, delirium, and circulatory collapse). It is also strictly contraindicated in serious pre-existing conditions like glaucoma and urinary retention.


Q: What happens if Dipatropin is taken too often?

Taking more than the prescribed amount risks signs of toxic overdosage, as documented in the official safety information. These signs can involve severe symptoms like restlessness, hallucinations, delirium, and circulatory collapse.


Q: Do certain foods lessen the effect of Dipatropin?

The official administration instructions state that the medication may be taken without regard to meals. This usually implies that food does not significantly impact the drug's absorption or lessen its therapeutic effect.

How should Dipatropin be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory agencies establish specific conditions for storing and disposing of medicines like Dipatropin to maintain product stability and safety. The official storage constraints focus primarily on environmental control and security.

Storage Condition Regulatory Requirement
Temperature Store at a temperature no greater than 25°C.
Environment Keep the medicine in a safe and dry place.
Child Safety Keep this medicine out of the sight and reach of children.
Disposal Do not dispose of medicines in wastewater or household trash.

Adherence to these official requirements ensures the medicine remains effective through its expiration date. Unused or expired medication should be disposed of by returning it to a pharmacist or following local regulated pharmaceutical collection programs to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dipatropin found in:

A-Z Index: